Efficacy and Local Tolerability of Topically Applied Heparin on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis

Stopped The Sponsor decided to terminate the study due to the low patient recruitment.

Conditions

• Haemodialysis

Interventions

• DRUG: Heparin 2,400 IU /ml Cutaneous Spray
• DRUG: Placebo Cutaneous Spray

Sponsor

Cyathus Exquirere Pharmaforschungsgmbh